Pricing a China Biotech Asset: NRDL, VBP & Why Domestic Economics Don't Travel

The China Discount, Defined

The “China discount” is a price-regime discount, not a quality discount. A Western buyer can acquire global or ex-China rights to a clinically credible Chinese asset for a relatively low entry cost because the seller's home-market economics are structurally capped by the state — not because the science is weaker. The discount is the wedge between two worlds: a domestic P&L that China's healthcare payer deliberately compresses, and an ex-China P&L that prices at full Western levels.

That wedge is real and large. Industry analysis has put Chinese asset upfronts at roughly 30% to 50% below comparable US or European deals at the same development stage, with some transactions historically 60% to 70% lower on upfronts and 40% to 50% smaller in total value — a gap that is now narrowing as data quality and deal precedent improve (Fierce Biotech, 2025). The point for a dealmaker is not the exact percentage; it is the cause. The discount exists largely because the price a molecule can command inside China is set, every year, by two instruments run by the National Healthcare Security Administration (NHSA): NRDL negotiation and volume-based procurement.

Understand those two machines and the rest of the China deal logic falls into place — why Chinese biotechs out-license so aggressively, why buyers insist on ex-China or global rights, and why the domestic sales line is the least important number in the model. For the broader landscape this sits inside, see our China biotech ecosystem guide and the deal-economics thesis in our China discount arbitrage analysis.

NRDL: Trading Price for Volume

NRDL is the annual negotiation that buys an innovative drug access to roughly 95% of the insured population in exchange for a deep, one-time price cut. The National Reimbursement Drug List is the formulary of China's basic medical insurance scheme. Each year the NHSA negotiates with manufacturers of patented and innovative drugs: list the molecule and the state will reimburse it for nearly the entire country; in return, the manufacturer accepts a steep haircut to the price.

The 2025 cycle, announced on December 7, 2025 and effective January 1, 2026, illustrates the trade. The NHSA shortlisted 129 of 311 off-list candidates, included 114 new products (50 of them Class 1 innovative drugs) — about 37% of candidates — and 88% of the drugs that reached negotiation were listed. Unlike earlier years, the NHSA did not publish an average price cut for new listings; Greenberg Traurig puts the concessions at over 60%, after an average of about 63% in 2024 (Greenberg Traurig, 2026; Pharmaceutical Technology, 2025). The updated list now runs to 3,253 entries. Inclusion is, in effect, a volume-for-price bargain: you surrender most of your unit price to reach the entire insured market at once.

Two structural features matter for valuation. First, an NRDL negotiated price is contracted for roughly two years, after which it is re-evaluated; the NHSA has moved to more moderate, more predictable renewal cuts (drugs listed more than four years see a halved reduction ratio, and those negotiated for more than eight years can roll into the standard List B), but the direction of travel on price is down, not up (nrdlplus.com). Second, the 2025 cycle introduced a genuine policy shift: alongside the basic NRDL, the NHSA launched the first-ever Commercial Health Insurance Innovative Drug List (CHIIDL, the unofficial “Category C” list) of 19 high-cost innovative drugs — CAR-T, bispecifics, Alzheimer's and rare-disease therapies — designed to protect premium pricing for breakthroughs that the basic scheme cannot afford at scale (pharmaceutical-technology.com; CMS Law, 2026).

The CHIIDL is the single most important recent signal that Beijing has noticed the problem this article describes: that pricing innovation at generic-adjacent levels discourages the very innovation it wants to nurture. It is early — pricing is set tripartite between the NHSA, commercial insurers and manufacturers, and average cuts were not disclosed — but for a dealmaker it reframes the domestic ceiling from “NRDL or nothing” to “NRDL for volume, CHIIDL for premium.” It does not, however, close the gap to Western prices.

VBP: Volume-Based Procurement

Volume-based procurement is the bulk tender that destroys the margin on off-patent originators and generics — cuts of 50% to 90%+ are routine. Where NRDL prices innovation at launch, VBP (also called centralized or pooled procurement) is what happens once a molecule loses exclusivity and a quality-certified generic equivalent exists. The NHSA aggregates demand from tens of thousands of public hospitals into one national tender and awards a guaranteed share of that volume to the lowest qualified bidders. The volume guarantee is the bait; the price collapse is the hook.

The model began with the November 2018 “4+7” pilot — 11 cities accounting for roughly a third of the Chinese pharmaceutical market — which delivered an average price cut of about 52% with a peak of 96%; Chia Tai Tianqing famously cut the hepatitis-B generic entecavir by 90% to win its tender (PharmaBoardroom; Clarivate). The pilot went national in 2019 and has since run through eleven rounds. The 11th national round, concluded in Shanghai on October 28, 2025, covered 55 drug varieties across anti-infectives, anti-tumor and allergy medicines; 453 products from 272 companies won, and for the first time the winning prices were not published, after rule changes meant to stop below-cost bidding (Caixin, 2025). The previous, 10th round had cut prices by more than 60% on average (Xinhua, 2025).

The squeeze is not optional. In a recent round, more than 200 companies making 60 off-patent drugs cut prices by an average of 48% to keep their hospital contracts, and multinationals that stay out of VBP typically forfeit 70% to 80% of the volume guarantee while still facing mandatory price cuts (Fierce Pharma; ScienceDirect systematic review, 2025). The practical decision for an originator is binary: bid low and keep volume, or exit the public-hospital channel. Either way, the mature-product cash flow that a Western model would treat as a durable annuity is, in China, a cliff.

The two instruments together define a molecule's entire China life: NRDL caps the price during the patented window, and VBP detonates it afterward. There is no high-price middle age. For how this interacts with manufacturing and supply-chain exposure, our BIOSECURE Act analysis covers the parallel geopolitical layer.

Why Domestic Economics Are Structurally Thin

Put NRDL and VBP together and the conclusion is unavoidable: a Chinese molecule's home-market P&L is engineered to be thin for its entire commercial life. In the West, a successful drug earns a high price across a long patent-protected window, then declines gradually. In China, the price starts compressed by NRDL and ends gutted by VBP, with the insured population — though enormous — delivering low per-patient revenue throughout.

The numbers make it concrete. By 2022 the four PD-1 inhibitors admitted to national insurance through reimbursement negotiation had all seen their prices fall sharply — camrelizumab took the deepest cut of the group — repricing domestic immuno-oncology far below its pre-negotiation launch levels (JOGH, 2025). A cost-effectiveness study illustrates the same gap at the unit level: it found the bispecific cadonilimab needed a price below about $210 per 125 mg to be cost-effective in China versus about $826 per 125 mg in the US — roughly a fourfold difference in the price the same molecule can defend in each market (Frontiers in Immunology, 2025).

This is why a Chinese biotech will rationally out-license an asset it believes in: keeping a thin domestic annuity while monetizing the rich ex-China rights upfront is often the value-maximizing move, especially for a company that needs capital and cannot fund a global Phase III alone. The license-out is not a sign of weakness; it is the logical response to a domestic ceiling. We unpack the buyer's side of that trade in our guide to in-licensing China biotech assets.

Why the China Price Does Not Travel

The single most important — and most often misunderstood — fact is that the low China price is a domestic regulatory artifact, not a property of the molecule. It does not, and largely cannot, travel with the asset to the US or Europe. A naive buyer might reason: if the drug sells for one-quarter of the US price in China, maybe we can launch cheaply and undercut Western incumbents. The market has already run that experiment, and it failed.

The cautionary case is Eli Lilly and Innovent's PD-1, sintilimab. Lilly proposed an aggressively low US price for the China-developed drug, explicitly pitching it as relief for the US healthcare system. In February 2022 the FDA's Oncologic Drugs Advisory Committee voted 14-1 that the China-only ORIENT-11 pivotal data could not be applied to US patients; the FDA declined to approve, and Lilly returned the ex-China rights to Innovent later that year (BioPharma Dive; Fierce Pharma, 2022). Two lessons compound for dealmakers. First, single-country Chinese data usually will not support a US filing — the ex-China value depends on a globally acceptable, often multi-regional, data package the buyer must fund. Second, a low price pledge buys nothing with the FDA; the agency reviews science, not generosity.

The pricing point cuts the other way too. Even if the data travels, the price should not: an ex-China licensee launching in the US will and should price at US levels, because US payers, list-to-net dynamics and competitive benchmarks — not China's NHSA — set the ceiling. The whole logic of the deal is that the molecule escapes the Chinese price regime when it crosses the border. (The one emerging caveat is international reference pricing: if US policy were to benchmark prices to low foreign markets, that escape would narrow — a dynamic we cover in our analysis of most-favored-nation drug pricing.)

Modeling China vs Ex-China Cash Flows

Model the asset as two separate businesses with two separate value drivers: a thin, regulated China annuity and a high-price ex-China franchise that carries the NPV. The mistake to avoid is anchoring the whole valuation on observed Chinese sales, then applying a Western multiple. That double-counts the discount: you inherit a price ceiling the molecule will never face once it leaves China.

In a risk-adjusted NPV framework, the practical adjustments are:

• Two price decks. Build the China revenue line on NRDL-negotiated (and, post-launch, VBP-eroded) pricing; build the ex-China line on Western net prices and reimbursement. Do not let the Chinese price bleed into the US/EU assumptions.
• A China terminal cliff, not a glide path. Model the loss of exclusivity in China as a VBP step-down of 50%–90%, not the gentle erosion a US loss-of-exclusivity curve assumes.
• Cost of a global data package. Add the cost and timeline of the multi-regional trials needed for FDA/EMA acceptance — the sintilimab tax — and risk-adjust the US/EU revenue for the probability that the data ultimately supports approval.
• Territory-weighted probability of success. The China asset may already carry de-risking from local data (see our China biotech news tracker for current approval and deal signals), but US/EU approval probability should reflect the bridging requirement, not the NMPA outcome.

For the underlying methodology — discounting, probability of success by phase, and how peak sales drive value — our rNPV valuation guide is the companion piece. The China-specific twist is simply that the two territories must be valued on two different price regimes, and the buyer is almost always paying for the one the seller cannot fully capture.

What It Means for Structuring a Deal

Because the value lives ex-China, the dominant structure is an ex-China or global license — and buyers pay for those territories, not the capped home market. The 2025 cohort proves the point at scale: roughly $135.7B in disclosed China-to-global deal value, including Innovent’s agreement with Takeda worth up to about $11.4B — one of the year’s largest China out-licensing deals — covering the PD-1×IL-2 IBI363 and two ADCs, with co-development and US co-commercialization (Yicai Global; DIA Global Forum, 2025–2026). The Hengrui–Braveheart Bio NewCo for cardiac myosin inhibitor HRS-1893 shows the smaller end: ex-Greater-China rights for $75M upfront and near-term milestones against up to $1.1B total (AO Shearman, 2025).

Three structuring implications follow for any cross-border deal:

• Clean territory carve-outs. The Chinese originator typically retains Greater China (where it can still run the thin domestic annuity and knows the NHSA system); the buyer takes ex-China or global. Clarity on the border is the whole game, because the price regimes differ on each side of it.
• Back-loaded consideration. Because the value is in markets the asset has not yet entered, deals lean on milestones and royalties over large upfronts — aligning payment with the ex-China data and approvals that actually unlock the value.
• NewCo structures. Spinning the ex-China rights into an offshore NewCo alongside Western investors lets the Chinese originator keep upside and de-risk geopolitical exposure while the asset is developed at Western prices — increasingly the preferred route, and one we structure directly.

For how these structures are negotiated in practice, see our out-licensing advisory and our team and cross-border network.